Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Coronary Artery Disease with Type 2 Diabetes
ChiCTR2600124836Phase 4Not yet recruiting
- Sponsor
- Pharmacy Department of Northern Jiangsu People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of finerenone in coronary arteriosclerosis, type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and 1 more (2 arms), sponsored by Pharmacy Department of Northern Jiangsu People's Hospital. Primary endpoints: Left ventricular ejection fraction, Urinary albumin to creatinine ratio and 3 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
coronary arteriosclerosistype 2 diabetes mellitus (T2DM)diabetic glomerulosclerosisheart failure (HF)
Beyond the preview
Go deeper on ChiCTR2600124836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124836.